Globus Medical Insider Sale: 10,000 Shares Disposed via 10b5-1 Plan
Rhea-AI Filing Summary
Director Ann D. Rhoads reported the sale of 10,000 shares of Class A Common Stock of Globus Medical, Inc. (GMED) on 09/15/2025 under a pre-established Rule 10b5-1 trading plan dated November 8, 2024. The weighted-average sale price was $58.46, with individual trade prices ranging from $58.22 to $58.81. After the reported dispositions, the reporting person beneficially owned 25,384 shares, held directly. The Form 4 was executed by an attorney-in-fact on behalf of the reporting person.
Positive
- Transaction executed under a Rule 10b5-1 plan, indicating the sale was prearranged and not an ad-hoc insider transaction.
- Complete disclosure of price range and weighted-average price ($58.22 - $58.81; weighted-average $58.46) with offer to provide per-trade details on request.
Negative
- Director reduced direct holdings by selling 10,000 shares, lowering beneficial ownership to 25,384 shares.
- Sale represents insider liquidity, which some investors may interpret negatively despite being under a 10b5-1 plan.
Insights
TL;DR: A director executed a planned sale of 10,000 GMED shares via a 10b5-1 plan; ownership was reduced but remains disclosed and routine.
The transaction was effected under a documented Rule 10b5-1 trading plan, which generally indicates the sale was prearranged and not based on material nonpublic information contemporaneously. The filing discloses a weighted-average price of $58.46 and a post-transaction direct beneficial ownership of 25,384 shares. For investors, this is a straightforward insider liquidity event rather than a governance or operational change. No derivatives or additional conditions are reported.
TL;DR: Director sale appears compliant and pre-planned; disclosure is complete with price range and 10b5-1 plan citation.
The Form 4 clearly identifies the filer as a director and specifies the November 8, 2024 10b5-1 plan as the mechanism for the sale, which supports procedural compliance. The filer provided the weighted-average price and disclosed willingness to supply transaction-level price details on request. The form shows direct ownership only and contains an attorney-in-fact signature, consistent with standard practice for timely reporting.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 10,000 | $58.46 | $585K |
Footnotes (1)
- This sale was effected pursuant to a Rule 10b5-1 trading plan dated November 8, 2024 executed by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $58.22-$58.81, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
